Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2008
07/08/2008CA2402364C Process for producing camptothecin
07/08/2008CA2396686C Transdermal therapeutic systems having improved stability and their production
07/08/2008CA2395077C Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
07/08/2008CA2387134C Cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
07/08/2008CA2384184C 17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
07/08/2008CA2383164C Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system
07/08/2008CA2368775C Treatment of cardiovascular and related pathologies
07/08/2008CA2360754C Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
07/08/2008CA2359354C Medicament for the treatment, prevention and diagnosis of infection due to chlamydia pneumoniae
07/08/2008CA2357073C Nucleic acid molecules comprising the promoter for the prostate cancer marker pca3 and uses thereof
07/08/2008CA2355825C Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma
07/08/2008CA2345364C Use of bisphosphonic acid derivatives for preparing a medicine for treating lameness
07/08/2008CA2344090C Compositions and methods for treating female sexual dysfunction
07/08/2008CA2339384C Improved method for targeted topical treatment of disease
07/08/2008CA2333154C Microemulsion preconcentrates containing a piperidine substance p antagonist
07/08/2008CA2332876C Efavirenz compressed tablet formulation
07/08/2008CA2330719C Synergistic compositions comprising an ascorbate and lysine for states related to extra cellular matrix degeneration
07/08/2008CA2330485C Oral formulation comprising biguanide and an organic acid
07/08/2008CA2330007C Improvements in macrolide production
07/08/2008CA2328025C Compositions containing fat-soluble vitamins
07/08/2008CA2327336C Aerosol composition
07/08/2008CA2317748C Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
07/08/2008CA2316277C Tablet for instant and prolonged release of one or more active substances
07/08/2008CA2308124C Methods and compositions for inducing tumor-specific cytotoxicity
07/08/2008CA2307878C Spine distraction implant
07/08/2008CA2306830C Use of adamantane amines or structurally similar compounds for combating borna disease virus and for the prevention and treatment of affective diseases and other disorders associated with bdv infections in humans and animals
07/08/2008CA2304947C Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
07/08/2008CA2301009C Skin care compositions and use
07/08/2008CA2300154C Sterile bioerodible implant device with improved biocompatability and method
07/08/2008CA2298681C Methods and compositions for overcoming resistance to biologic and chemotherapy
07/08/2008CA2286631C Solid compositions suitable for oral administration comprising l-carnitine or an alkanoyl-l-carnitinecholine tartrate
07/08/2008CA2285928C Allergen formulation comprising tyrosine and 3 de-o-acylated monophosphoryl lipid a
07/08/2008CA2285550C Solid compositions suitable for oral administration comprising l-carnitine and alkanoyl-l-carnitine magnesium tartrate
07/08/2008CA2285380C Solid compositions suitable for oral administration comprising non hygroscopic salts of l-carnitine and alkanoyl-l-carnitine with 2-amino-ethanesulfonic acid
07/08/2008CA2280770C Gene therapy for alleviating erectile dysfunction
07/08/2008CA2271268C Therapeutic and cosmetic compositions comprising an extract of crude shark liver oil, their use and method for the preparation thereof
07/08/2008CA2265917C Method for using oligonucleotides having modified cpg dinucleosides
07/08/2008CA2253593C Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
07/08/2008CA2251656C Pharmaceutical compositions containing tyloxapol for administration to the respiratory tract
07/08/2008CA2250712C Chimeric isoprenoid synthases and uses thereof
07/08/2008CA2231509C Protein tyrosine kinase inhibitors for treating osteoarthritis
07/08/2008CA2229228C Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine
07/08/2008CA2221455C Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids
07/08/2008CA2218884C Synthesis of the breast tumor-associated antigen defined by monoclonal antibody mbr1 and uses thereof
07/08/2008CA2211939C Process for producing rhein and diacerhein
07/08/2008CA2200324C 4a-aryldecahydroisoquinoline compounds and medicinal use of the same
07/08/2008CA2198706C Methods for the treatment of inflammatory joint disease
07/08/2008CA2188029C Porphocyanine and cnc-expanded porphyrins
07/08/2008CA2162587C Therapeutic inhibitor of vascular smooth muscle cells
07/08/2008CA2117782C Use of renin-angiotensin antagonist for reducing post myocardial infarct morbidity and mortality
07/03/2008WO2008080170A1 Mixed drug aerosol compositiions
07/03/2008WO2008080162A2 Anti-cholesterolemic compounds and methods of use
07/03/2008WO2008080134A2 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
07/03/2008WO2008080120A2 3-amino chromane derivatives
07/03/2008WO2008080110A1 Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
07/03/2008WO2008080092A2 Compositions comprising bile acid sequestrants for treating esophageal disorders
07/03/2008WO2008080064A1 Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders
07/03/2008WO2008080060A2 4-se-thymidine derivatives, 4-se-uridine derivatives, di (2-cyanoethyl) diselenide, and methods
07/03/2008WO2008080056A2 Pyridazinones and furan-containing compounds
07/03/2008WO2008080037A2 Carotenoids of enhanced bioavailability
07/03/2008WO2008080015A2 Compounds and methods for kinase modulation, and indications therefor
07/03/2008WO2008080012A1 Reduction of cardiovascular symptoms
07/03/2008WO2008080009A2 Neuroprotection by blood flow stabilization
07/03/2008WO2008080005A1 Food products having caffeine incorporated therein
07/03/2008WO2008080001A2 Compounds and methods for kinase modulation, and indications therefor
07/03/2008WO2008079980A1 Inhibitors of protein kinase c-delta for the treatment of glaucoma
07/03/2008WO2008079971A1 A method of producing stable oxy-chloro acid
07/03/2008WO2008079968A1 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
07/03/2008WO2008079965A1 Substituted heterocycles as janus kinase inhibitors
07/03/2008WO2008079945A2 Rock inhibitors and uses thereof
07/03/2008WO2008079933A2 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
07/03/2008WO2008079924A1 Immune response modifier compositions and methods
07/03/2008WO2008079918A1 Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
07/03/2008WO2008079909A1 Pyrrolo [2,3-b] pyridines as kinase modulators
07/03/2008WO2008079907A1 Compositions and methods for inhibition of the jak pathway
07/03/2008WO2008079906A1 Pyrrolo [2, 3-b] pyridine derivatives as kinase modulators
07/03/2008WO2008079903A1 Pyrrolo [2, 3-b] pyridine derivatives as kinase modulators
07/03/2008WO2008079898A1 Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
07/03/2008WO2008079880A1 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of glaucoma and ocular hypertension
07/03/2008WO2008079868A1 Clonidine composition and method of use
07/03/2008WO2008079857A1 Crystalline forms of aryl-substituted pyrazole-amide compounds
07/03/2008WO2008079849A2 Antibodies to insulin-like growth factor receptor
07/03/2008WO2008079848A1 Compounds and uses thereof
07/03/2008WO2008079847A1 Compounds and uses thereof
07/03/2008WO2008079839A1 Compounds and uses thereof
07/03/2008WO2008079838A1 Compounds and uses thereof
07/03/2008WO2008079836A2 Macrocyclic factor viia inhibitors useful as anticoagulants
07/03/2008WO2008079814A2 Mapk/erk kinase inhibitors
07/03/2008WO2008079787A2 Glucokinase activators
07/03/2008WO2008079783A1 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
07/03/2008WO2008079759A1 Bicyclic lactam factor viia inhibitors useful as anticoagulants
07/03/2008WO2008079735A1 Imidazopyridine inhibitors of iap
07/03/2008WO2008079728A2 Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
07/03/2008WO2008079721A1 Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
07/03/2008WO2008079720A1 Alpha-2b receptor agonist and anticonvulsant compositions for treatng chronic pain
07/03/2008WO2008079719A1 Pyrimidine kinase inhibitors
07/03/2008WO2008079697A2 Method of treating mucin deficiency with an active pharmaceutical and related composition
07/03/2008WO2008079687A1 Novel compounds as cannabinoid receptor ligands and uses thereof
07/03/2008WO2008079683A2 N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
07/03/2008WO2008079674A2 Processes for making cyclic lipid implants for intraocular use